Abstract:Objective: GABAA receptor subunit mutations pose a significant risk for genetic generalized epilepsy; however, there are over 150 identified variants, many with unknown or unvalidated pathogenicity. We aimed to develop in vivo models for testing GABAA receptor variants using the model organism, Caenorhabditis elegans. Methods: CRISPR-Cas9 gene editing was used to create a complete deletion of unc-49, a C. elegans GABAA receptor, and to create homozygous epilepsy-associated mutations in the endogenous unc-49 gene. The unc-49 deletion strain was rescued with transgenes for either the C. elegans unc-49B subunit or the α1, β3, and γ2 subunits for the human GABAA receptor. All newly created strains were analyzed for phenotype and compared against existing unc-49 mutations. Results: Nematodes with a full genetic deletion of the entire unc-49 locus were compared with existing unc-49 mutations in three separate phenotypic assays-coordinated locomotion, shrinker frequency and seizure-like convulsions. The full unc-49 deletion exhibited reduced locomotion and increased shrinker frequency and PTZ-induced convulsions, but were not found to be phenotypically stronger than existing unc-49 mutations. Rescue with the unc-49B subunit or creation of humanized worms for the GABAA receptor both showed partial phenotypic rescue for all three phenotypes investigated. Finally, two epilepsy-associated variants were analyzed and deemed to be loss of function, thus validating their pathogenicity. Significance: These findings establish C. elegans as a genetic model to investigate GABAA receptor mutations and delineate a platform for validating associated variants in any epilepsy-associated gene. Plain language summary: Epilepsy is a complex human disease that can be caused by mutations in specific genes. Many possible mutations have been identified, but it is unknown for most of them whether they cause the disease. We tested the role of mutations in one specific gene using a small microscopic worm as an animal model. Our results establish this worm as a model for epilepsy and confirm that the two unknown mutations are likely to cause the disease.

Genetic modeling of GNAO1 disorder delineates mechanisms of Go dysfunction

Gnao1 is a molecular switch that regulates the Rho signaling pathway in differentiating neurons

AAV9-Mediated Intrastriatal Delivery of GNAO1 Reduces Hyperlocomotion in Gnao1 Heterozygous R209H Mutant Mice

Cortical neurons obtained from patient-derived iPSCs with GNAO1 p.G203R variant show altered differentiation and functional properties

Modeling neurodevelopmental disorder-associated human AGO1 mutations in Caenorhabditis elegans Argonaute alg-1

GNAO1 Mutations Affecting the N‐Terminal α‐Helix of Gαo Lead to Parkinsonism

Gαo is a major determinant of cAMP signaling in the pathophysiology of movement disorders.

CRISPR/Cas9-generated mouse model with humanizing single-base substitution in the Gnao1 for safety studies of RNA therapeutics

Zinc for GNAO1 encephalopathy: Preclinical profiling and a clinical case

Phenotypes of GNAO1 Variants in a Chinese Cohort

Functional analysis of epilepsy-associated GABAA receptor mutations using Caenorhabditis elegans

Neurodevelopmental defects in a mouse model of O-GlcNAc transferase intellectual disability

Neuron specific quantitation of Gαolf expression and signaling in murine brain tissue

Glutaminase C Overexpression in the Brain Induces Learning Deficits, Synaptic Dysfunctions, and Neuroinflammation in Mice.

Conditional Knockout of Striatal Gnal Produces Dystonia-like Motor Phenotypes

De Novo Variants in AGO1 Recapitulate a Heterogeneous Neurodevelopmental Disorder Phenotype

RNA Interference Effectors Selectively Silence the Pathogenic Variant GNAO1 c.607 G > A In Vitro

Novel GNE missense variants impair de novo sialylation and cause defective angiogenesis in the developing brain in mice

Effective knockdown-replace gene therapy in a novel mouse model of DNM1 developmental and epileptic encephalopathy

Molecular Dynamic Simulations to Determine Individualized Therapy: Tetrabenazine for the GNAO1 Encephalopathy E246K Variant

Neuronal loss of Impairs O-glycosylation and Leads to Neurobehavioral Deficits Mimicking GALNT2-CDG